1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2016

Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2016

  • December 2016
  • -
  • Global Markets Direct
  • -
  • 58 pages

Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Hyperphosphatemia In Chronic Kidney Disease – Pipeline Review, H2 2016, provides an overview of the Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline landscape.

Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus and rash. Treatment includes phosphate binders and diuretics.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Hyperphosphatemia In Chronic Kidney Disease – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 2, 1, 1 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders).
- The pipeline guide reviews pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hyperphosphatemia In Chronic Kidney Disease Overview 7
Therapeutics Development 8
Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease - Overview 8
Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis 9
Hyperphosphatemia In Chronic Kidney Disease - Therapeutics under Development by Companies 10
Hyperphosphatemia In Chronic Kidney Disease - Therapeutics under Investigation by Universities/Institutes 11
Hyperphosphatemia In Chronic Kidney Disease - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Hyperphosphatemia In Chronic Kidney Disease - Products under Development by Companies 15
Hyperphosphatemia In Chronic Kidney Disease - Products under Investigation by Universities/Institutes 16
Hyperphosphatemia In Chronic Kidney Disease - Companies Involved in Therapeutics Development 17
3SBio Inc 17
Ardelyx Inc 18
Daiichi Sankyo Company Ltd 19
Medice Arzneimittel Putter GmbH and Co KG 20
OPKO Health Inc 21
PDX Pharmaceuticals LLC 22
Shield Therapeutics Plc 23
Spectrum Pharmaceuticals Inc 24
Toray Industries Inc 25
Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 32
Drug Profiles 34
DS-2330 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
RandD Progress 34
fermagate - Drug Profile 35
Product Description 35
Mechanism Of Action 35
RandD Progress 35
JPH-101 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
RandD Progress 36
niacinamide - Drug Profile 37
Product Description 37
Mechanism Of Action 37
RandD Progress 37
PDX-004 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
RandD Progress 38
PT-20 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
RandD Progress 39
RDX-002 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
RandD Progress 40
sevelamer carbonate - Drug Profile 41
Product Description 41
Mechanism Of Action 41
RandD Progress 41
Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD - Drug Profile 42
Product Description 42
Mechanism Of Action 42
RandD Progress 42
Small Molecules to Target Phosphate for Hyperphosphatemia In Chronic Kidney Disease - Drug Profile 43
Product Description 43
Mechanism Of Action 43
RandD Progress 43
SPI-014 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
RandD Progress 44
tenapanor hydrochloride - Drug Profile 45
Product Description 45
Mechanism Of Action 45
RandD Progress 45
TRK-390 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
RandD Progress 49
VS-501 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
RandD Progress 50
Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects 51
Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products 52
Hyperphosphatemia In Chronic Kidney Disease - Product Development Milestones 53
Featured News and Press Releases 53
May 07, 2015: Phosphate Therapeutics announces positive results in the PEACH pivotal study of its novel phosphate binder (PT20) for the treatment of hyperphosphataemia 53
Feb 02, 2015: Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis 54
Jan 07, 2013: Spectrum Pharma Announces Positive RenaZorb Phase I Clinical Data Demonstrating Robust Activity In Easy-to-swallow Pill Formulation 54
May 29, 2012: Spectrum Pharma Announces Enrollment Of First Group Of Patients In Phase I Clinical Trial Of RenaZorb 55
Dec 05, 2011: Spectrum Pharmaceuticals Files Investigational New Drug Application With FDA For SPI-014 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58




List of Tables
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H2 2016 8
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by 3SBio Inc, H2 2016 17
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Ardelyx Inc, H2 2016 18
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 19
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Medice Arzneimittel Putter GmbH and Co KG, H2 2016 20
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by OPKO Health Inc, H2 2016 21
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by PDX Pharmaceuticals LLC, H2 2016 22
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Shield Therapeutics Plc, H2 2016 23
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016 24
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Toray Industries Inc, H2 2016 25
Assessment by Monotherapy Products, H2 2016 26
Number of Products by Stage and Target, H2 2016 28
Number of Products by Stage and Mechanism of Action, H2 2016 30
Number of Products by Stage and Route of Administration, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 33
Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects, H2 2016 51
Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products, H2 2016 52




List of Figures
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H2 2016 8
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Assessment by Monotherapy Products, H2 2016 26
Number of Products by Top 10 Targets, H2 2016 27
Number of Products by Stage and Top 10 Targets, H2 2016 27
Number of Products by Mechanism of Actions, H2 2016 29
Number of Products by Stage and Mechanism of Actions, H2 2016 29
Number of Products by Stage and Routes of Administration, H2 2016 31
Number of Products by Molecule Types, H2 2016 32
Number of Products by Stage and Molecule Types, H2 2016 32

Companies Mentioned
3SBio Inc
Ardelyx Inc
Daiichi Sankyo Company Ltd
Medice Arzneimittel Putter GmbH and Co KG
OPKO Health Inc
PDX Pharmaceuticals LLC
Shield Therapeutics Plc
Spectrum Pharmaceuticals Inc
Toray Industries Inc

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Diabetes & Obesity Drug Development Pipeline Review, 2016

Diabetes & Obesity Drug Development Pipeline Review, 2016

  • $ 3995
  • Company report
  • December 2016
  • by GBI Research

Diabetes & Obesity Drug Development Pipeline Review, 2016 Summary The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type ...

G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Pipeline Review, H2 2016

G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ...

Oxysterols Receptor LXR Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or Ubiquitously Expressed Nuclear Receptor or LXRB or NR1H2) - Pipeline Review, H2 2016

Oxysterols Receptor LXR Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or Ubiquitously Expressed Nuclear Receptor or LXRB or NR1H2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Oxysterols Receptor LXR Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or Ubiquitously Expressed Nuclear Receptor or LXRB or NR1H2) - Pipeline Review, ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.